Research
Hormonal
Occupational exposure to pesticides and biocides is associated with an increased risk of thyroid cancer, particularly in male adults.
Workers in agriculture or pest control should strictly adhere to safety protocols to minimize exposure to pesticides and biocides, as these chemicals are linked to an increased risk of thyroid cancer, particularly in men.
GoodSupportsHIGH confidence
There was a significantly increased of thyroid cancer risk associated with exposure to pesticides and biocides (OR = 1.65; IC 95% 1.16–2.35) and this risk was more marked in male adults (OR = 3.11; IC 95% 1.25–7.72).
Why this rating
Cites a specific case-control study with odds ratios, but the overall paper notes that conclusive results for all cancers are not always possible due to scarce cases.
Source
Endocrine Disrupting Chemicals: Effects on Endocrine Glands
Rosa Lauretta et al. · Frontiers in Endocrinology · 2019
DOI 10.3389/fendo.2019.00178
narrative_reviewCited 332×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Exposure to endocrine-disrupting chemicals (EDCs) during early development can alter adipose tissue homeostasis and energy regulation, predisposing individuals to obesity and metabolic syndrome even with low-calorie diets and increased physical activity.Moderate
- Exposure to specific endocrine-disrupting chemicals (e.g., phthalates, BPA, vinclozolin) is associated with an increased risk of Testicular Dysgenesis Syndrome (TDS) and reduced male fertility.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →